The Europe Diabetic Neuropathy Treatment Market would witness market growth of 6.9% CAGR during the forecast period (2024-2031).
The Germany market dominated the Europe Diabetic Neuropathy Treatment Market by Country in 2023, and would continue to be a dominant market till 2031; thereby, achieving a market value of $454 million by 2031. The UK market is exhibiting a CAGR of 6% during (2024 - 2031). Additionally, The France market would experience a CAGR of 7.8% during (2024 - 2031).
As the condition's prevalence rises and the need for effective therapeutic interventions intensifies, the market for it is undergoing a rapid evolution. In recent years, there have been significant advancements in the understanding of this and the development of new treatment options.
Additionally, due to these developments, the management of this has shifted to place more importance on early detection and intervention to impede or halt the progression of nerve damage.
European research and innovation efforts contribute to developing novel and more effective treatment modalities for diabetic neuropathy. This includes discovering new pharmacological agents, biotechnological therapies, and medical devices specifically designed to target neuropathic symptoms. According to the European Commission, research and innovation on diabetes and related factors, such as obesity, has been a longstanding priority for the EU. Over EUR 1.25 billion has been devoted to support research in the last decade.
Based on Distribution Channel, the market is segmented into Hospitals Pharmacies, Retail Pharmacies and Others. Based on Drug Class, the market is segmented into Non-Steroidal Anti-inflammatory Drugs (NSAIDs), Antidepressants, Opioid, Capsaicin and Others. Based on Disorder Type, the market is segmented into Peripheral Neuropathy, Autonomic Neuropathy, Proximal Neuropathy and Focal Neuropathy. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The Germany market dominated the Europe Diabetic Neuropathy Treatment Market by Country in 2023, and would continue to be a dominant market till 2031; thereby, achieving a market value of $454 million by 2031. The UK market is exhibiting a CAGR of 6% during (2024 - 2031). Additionally, The France market would experience a CAGR of 7.8% during (2024 - 2031).
As the condition's prevalence rises and the need for effective therapeutic interventions intensifies, the market for it is undergoing a rapid evolution. In recent years, there have been significant advancements in the understanding of this and the development of new treatment options.
Additionally, due to these developments, the management of this has shifted to place more importance on early detection and intervention to impede or halt the progression of nerve damage.
European research and innovation efforts contribute to developing novel and more effective treatment modalities for diabetic neuropathy. This includes discovering new pharmacological agents, biotechnological therapies, and medical devices specifically designed to target neuropathic symptoms. According to the European Commission, research and innovation on diabetes and related factors, such as obesity, has been a longstanding priority for the EU. Over EUR 1.25 billion has been devoted to support research in the last decade.
Based on Distribution Channel, the market is segmented into Hospitals Pharmacies, Retail Pharmacies and Others. Based on Drug Class, the market is segmented into Non-Steroidal Anti-inflammatory Drugs (NSAIDs), Antidepressants, Opioid, Capsaicin and Others. Based on Disorder Type, the market is segmented into Peripheral Neuropathy, Autonomic Neuropathy, Proximal Neuropathy and Focal Neuropathy. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
List of Key Companies Profiled
- Abbott Laboratories
- Eli Lilly And Company
- Pfizer, Inc.
- Lupin Limited
- Astellas Pharma, Inc.
- Glenmark Pharmaceuticals Limited
- Boehringer Ingelheim International GmbH
- Novartis AG
- McKesson Corporation
- GlaxoSmithKline PLC (GSK)
Market Report Segmentation
By Distribution Channel- Hospitals Pharmacies
- Retail Pharmacies
- Others
- Non-Steroidal Anti-inflammatory Drugs (NSAIDs)
- Antidepressants
- Opioid
- Capsaicin
- Others
- Peripheral Neuropathy
- Autonomic Neuropathy
- Proximal Neuropathy
- Focal Neuropathy
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market at a Glance
Chapter 3. Market Overview
Chapter 4. Europe Diabetic Neuropathy Treatment Market by Distribution Channel
Chapter 5. Europe Diabetic Neuropathy Treatment Market by Drug Class
Chapter 6. Europe Diabetic Neuropathy Treatment Market by Disorder Type
Chapter 7. Europe Diabetic Neuropathy Treatment Market by Country
Chapter 8. Company Profiles
Companies Mentioned
- Abbott Laboratories
- Eli Lilly And Company
- Pfizer, Inc.
- Lupin Limited
- Astellas Pharma, Inc.
- Glenmark Pharmaceuticals Limited
- Boehringer Ingelheim International GmbH
- Novartis AG
- McKesson Corporation
- GlaxoSmithKline PLC (GSK)
Methodology
LOADING...
